JP2015524066A - 慢性弁膜疾患を診断するための方法 - Google Patents
慢性弁膜疾患を診断するための方法 Download PDFInfo
- Publication number
- JP2015524066A JP2015524066A JP2015516104A JP2015516104A JP2015524066A JP 2015524066 A JP2015524066 A JP 2015524066A JP 2015516104 A JP2015516104 A JP 2015516104A JP 2015516104 A JP2015516104 A JP 2015516104A JP 2015524066 A JP2015524066 A JP 2015524066A
- Authority
- JP
- Japan
- Prior art keywords
- animal
- valvular disease
- chronic valvular
- sample
- amount
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims abstract description 82
- 201000010099 disease Diseases 0.000 title claims abstract description 81
- 230000001684 chronic effect Effects 0.000 title claims abstract description 78
- 238000000034 method Methods 0.000 title claims abstract description 40
- 241001465754 Metazoa Species 0.000 claims abstract description 92
- 239000002207 metabolite Substances 0.000 claims abstract description 79
- 239000000523 sample Substances 0.000 claims description 47
- 238000003745 diagnosis Methods 0.000 claims description 20
- 229960004956 glycerylphosphorylcholine Drugs 0.000 claims description 15
- YDGMGEXADBMOMJ-UHFFFAOYSA-N asymmetrical dimethylarginine Natural products CN(C)C(N)=NCCCC(N)C(O)=O YDGMGEXADBMOMJ-UHFFFAOYSA-N 0.000 claims description 14
- 241000282465 Canis Species 0.000 claims description 12
- 239000012805 animal sample Substances 0.000 claims description 12
- 239000012472 biological sample Substances 0.000 claims description 12
- NWGZOALPWZDXNG-LURJTMIESA-N (2s)-5-(diaminomethylideneamino)-2-(dimethylamino)pentanoic acid Chemical compound CN(C)[C@H](C(O)=O)CCCNC(N)=N NWGZOALPWZDXNG-LURJTMIESA-N 0.000 claims description 7
- ZNHVWPKMFKADKW-UHFFFAOYSA-N 12-HETE Chemical compound CCCCCC=CCC(O)C=CC=CCC=CCCCC(O)=O ZNHVWPKMFKADKW-UHFFFAOYSA-N 0.000 claims description 7
- ZNHVWPKMFKADKW-ZYBDYUKJSA-N 12-HETE Natural products CCCCC\C=C/C[C@@H](O)\C=C\C=C/C\C=C/CCCC(O)=O ZNHVWPKMFKADKW-ZYBDYUKJSA-N 0.000 claims description 7
- JHPNVNIEXXLNTR-UHFFFAOYSA-N 4-(trimethylammonio)butanoate Chemical compound C[N+](C)(C)CCCC([O-])=O JHPNVNIEXXLNTR-UHFFFAOYSA-N 0.000 claims description 7
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 7
- 108010053070 Glutathione Disulfide Proteins 0.000 claims description 7
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 claims description 7
- YDGMGEXADBMOMJ-LURJTMIESA-N N(g)-dimethylarginine Chemical compound CN(C)C(\N)=N\CCC[C@H](N)C(O)=O YDGMGEXADBMOMJ-LURJTMIESA-N 0.000 claims description 7
- SQVRNKJHWKZAKO-LUWBGTNYSA-N N-acetylneuraminic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)CC(O)(C(O)=O)O[C@H]1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-LUWBGTNYSA-N 0.000 claims description 7
- VVPRQWTYSNDTEA-LLVKDONJSA-N O-hexanoyl-L-carnitine Chemical compound CCCCCC(=O)O[C@H](CC([O-])=O)C[N+](C)(C)C VVPRQWTYSNDTEA-LLVKDONJSA-N 0.000 claims description 7
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 7
- 239000008103 glucose Substances 0.000 claims description 7
- YPZRWBKMTBYPTK-BJDJZHNGSA-N glutathione disulfide Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@H](C(=O)NCC(O)=O)CSSC[C@@H](C(=O)NCC(O)=O)NC(=O)CC[C@H](N)C(O)=O YPZRWBKMTBYPTK-BJDJZHNGSA-N 0.000 claims description 7
- YPZRWBKMTBYPTK-UHFFFAOYSA-N oxidized gamma-L-glutamyl-L-cysteinylglycine Natural products OC(=O)C(N)CCC(=O)NC(C(=O)NCC(O)=O)CSSCC(C(=O)NCC(O)=O)NC(=O)CCC(N)C(O)=O YPZRWBKMTBYPTK-UHFFFAOYSA-N 0.000 claims description 7
- HAEVNYBCYZZDFL-MRVPVSSYSA-N succinyl-L-carnitine Chemical compound C[N+](C)(C)C[C@@H](CC([O-])=O)OC(=O)CCC(O)=O HAEVNYBCYZZDFL-MRVPVSSYSA-N 0.000 claims description 7
- FLIACVVOZYBSBS-UHFFFAOYSA-N Methyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC FLIACVVOZYBSBS-UHFFFAOYSA-N 0.000 claims description 6
- XNRNNGPBEPRNAR-UHFFFAOYSA-N Thromboxane B2 Natural products CCCCCC(O)C=CC1OC(O)CC(O)C1CC=CCCCC(O)=O XNRNNGPBEPRNAR-UHFFFAOYSA-N 0.000 claims description 6
- 210000002966 serum Anatomy 0.000 claims description 6
- -1 cis-aconidate Chemical compound 0.000 claims description 5
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims description 4
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 claims description 4
- YYQVCMMXPIJVHY-ZOIJLGJPSA-N 1-[(11Z,14Z)]-icosadienoyl-sn-glycero-3-phosphocholine Chemical compound CCCCC\C=C/C\C=C/CCCCCCCCCC(=O)OC[C@@H](O)COP([O-])(=O)OCC[N+](C)(C)C YYQVCMMXPIJVHY-ZOIJLGJPSA-N 0.000 claims description 4
- UHDGCWIWMRVCDJ-UHFFFAOYSA-N 1-beta-D-Xylofuranosyl-NH-Cytosine Natural products O=C1N=C(N)C=CN1C1C(O)C(O)C(CO)O1 UHDGCWIWMRVCDJ-UHFFFAOYSA-N 0.000 claims description 4
- SPJFYYJXNPEZDW-FTJOPAKQSA-N 1-linoleoyl-sn-glycero-3-phosphocholine Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(=O)OC[C@@H](O)COP([O-])(=O)OCC[N+](C)(C)C SPJFYYJXNPEZDW-FTJOPAKQSA-N 0.000 claims description 4
- MXAFDFDAIFZFET-CZDOQZASSA-N 1-stearoyl-sn-glycero-3-phospho-1D-myo-inositol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)COP(O)(=O)O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](O)[C@H]1O MXAFDFDAIFZFET-CZDOQZASSA-N 0.000 claims description 4
- MCRJLMXYVFDXLS-QGQBRVLBSA-N 12-HEPE Chemical compound CC\C=C/C\C=C/CC(O)\C=C\C=C/C\C=C/CCCC(O)=O MCRJLMXYVFDXLS-QGQBRVLBSA-N 0.000 claims description 4
- FRYOUKNFWFXASU-UHFFFAOYSA-N 2-(methylamino)acetic acid Chemical group CNCC(O)=O.CNCC(O)=O FRYOUKNFWFXASU-UHFFFAOYSA-N 0.000 claims description 4
- YAMUFBLWGFFICM-PTGWMXDISA-O 2-[hydroxy-[(2r)-2-hydroxy-3-[(z)-octadec-9-enoyl]oxypropoxy]phosphoryl]oxyethyl-trimethylazanium Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)COP(O)(=O)OCC[N+](C)(C)C YAMUFBLWGFFICM-PTGWMXDISA-O 0.000 claims description 4
- AXFYFNCPONWUHW-UHFFFAOYSA-M 3-hydroxyisovalerate Chemical compound CC(C)(O)CC([O-])=O AXFYFNCPONWUHW-UHFFFAOYSA-M 0.000 claims description 4
- HHDDCCUIIUWNGJ-UHFFFAOYSA-N 3-hydroxypyruvic acid Chemical compound OCC(=O)C(O)=O HHDDCCUIIUWNGJ-UHFFFAOYSA-N 0.000 claims description 4
- YHXHKYRQLYQUIH-UHFFFAOYSA-M 4-hydroxymandelate Chemical compound [O-]C(=O)C(O)C1=CC=C(O)C=C1 YHXHKYRQLYQUIH-UHFFFAOYSA-M 0.000 claims description 4
- UHDGCWIWMRVCDJ-PSQAKQOGSA-N Cytidine Natural products O=C1N=C(N)C=CN1[C@@H]1[C@@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-PSQAKQOGSA-N 0.000 claims description 4
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims description 4
- 239000008777 Glycerylphosphorylcholine Substances 0.000 claims description 4
- RQNSKRXMANOPQY-UHFFFAOYSA-N L-L-gamma-Glutamylmethionine Natural products CSCCC(C(O)=O)NC(=O)CCC(N)C(O)=O RQNSKRXMANOPQY-UHFFFAOYSA-N 0.000 claims description 4
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims description 4
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 claims description 4
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims description 4
- UNUYMBPXEFMLNW-DWVDDHQFSA-N N-[(9-beta-D-ribofuranosylpurin-6-yl)carbamoyl]threonine Chemical compound C1=NC=2C(NC(=O)N[C@@H]([C@H](O)C)C(O)=O)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O UNUYMBPXEFMLNW-DWVDDHQFSA-N 0.000 claims description 4
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims description 4
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims description 4
- 239000004473 Threonine Substances 0.000 claims description 4
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims description 4
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims description 4
- SUHOQUVVVLNYQR-MRVPVSSYSA-N choline alfoscerate Chemical compound C[N+](C)(C)CCOP([O-])(=O)OC[C@H](O)CO SUHOQUVVVLNYQR-MRVPVSSYSA-N 0.000 claims description 4
- UHDGCWIWMRVCDJ-ZAKLUEHWSA-N cytidine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-ZAKLUEHWSA-N 0.000 claims description 4
- RQNSKRXMANOPQY-BQBZGAKWSA-N gamma-Glu-Met Chemical compound CSCC[C@@H](C(O)=O)NC(=O)CC[C@H](N)C(O)=O RQNSKRXMANOPQY-BQBZGAKWSA-N 0.000 claims description 4
- 235000013922 glutamic acid Nutrition 0.000 claims description 4
- 239000004220 glutamic acid Substances 0.000 claims description 4
- 229940049920 malate Drugs 0.000 claims description 4
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 claims description 4
- KEMQGTRYUADPNZ-UHFFFAOYSA-M margarate Chemical compound CCCCCCCCCCCCCCCCC([O-])=O KEMQGTRYUADPNZ-UHFFFAOYSA-M 0.000 claims description 4
- 229930182817 methionine Natural products 0.000 claims description 4
- 229940014662 pantothenate Drugs 0.000 claims description 4
- 235000019161 pantothenic acid Nutrition 0.000 claims description 4
- 239000011713 pantothenic acid Substances 0.000 claims description 4
- WQEPLUUGTLDZJY-UHFFFAOYSA-M pentadecanoate Chemical compound CCCCCCCCCCCCCCC([O-])=O WQEPLUUGTLDZJY-UHFFFAOYSA-M 0.000 claims description 4
- 239000004474 valine Substances 0.000 claims description 4
- LFUDDCMNKWEORN-ZXEGGCGDSA-N 1-[(9Z)-hexadecenoyl]-sn-glycero-3-phosphocholine Chemical compound CCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)COP([O-])(=O)OCC[N+](C)(C)C LFUDDCMNKWEORN-ZXEGGCGDSA-N 0.000 claims description 3
- JKRDADVRIYVCCY-UHFFFAOYSA-N 2-hydroxyoctanoic acid Chemical compound CCCCCCC(O)C(O)=O JKRDADVRIYVCCY-UHFFFAOYSA-N 0.000 claims description 3
- JPIJQSOTBSSVTP-PWNYCUMCSA-N D-erythronic acid Chemical compound OC[C@@H](O)[C@@H](O)C(O)=O JPIJQSOTBSSVTP-PWNYCUMCSA-N 0.000 claims description 3
- FDJKUWYYUZCUJX-PGIATKPXSA-N N-glycoloylneuraminic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@@H]1OC(O)(C(O)=O)C[C@H](O)[C@H]1NC(=O)CO FDJKUWYYUZCUJX-PGIATKPXSA-N 0.000 claims description 3
- GTZCVFVGUGFEME-IWQZZHSRSA-N cis-aconitic acid Chemical compound OC(=O)C\C(C(O)=O)=C\C(O)=O GTZCVFVGUGFEME-IWQZZHSRSA-N 0.000 claims description 2
- XNRNNGPBEPRNAR-JQBLCGNGSA-N thromboxane B2 Chemical compound CCCCC[C@H](O)\C=C\[C@H]1OC(O)C[C@H](O)[C@@H]1C\C=C/CCCC(O)=O XNRNNGPBEPRNAR-JQBLCGNGSA-N 0.000 claims 4
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 claims 2
- 239000002253 acid Substances 0.000 claims 1
- 230000000052 comparative effect Effects 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 238000004949 mass spectrometry Methods 0.000 description 25
- 238000004811 liquid chromatography Methods 0.000 description 14
- 239000000090 biomarker Substances 0.000 description 13
- 150000001875 compounds Chemical class 0.000 description 8
- 238000004817 gas chromatography Methods 0.000 description 7
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 241000282472 Canis lupus familiaris Species 0.000 description 5
- 239000000284 extract Substances 0.000 description 5
- 208000019622 heart disease Diseases 0.000 description 5
- 238000004252 FT/ICR mass spectrometry Methods 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 238000000132 electrospray ionisation Methods 0.000 description 4
- 238000005040 ion trap Methods 0.000 description 4
- 150000002500 ions Chemical class 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 206010027727 Mitral valve incompetence Diseases 0.000 description 3
- 230000002378 acidificating effect Effects 0.000 description 3
- 230000000875 corresponding effect Effects 0.000 description 3
- 238000013075 data extraction Methods 0.000 description 3
- 238000002290 gas chromatography-mass spectrometry Methods 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- FMNQRUKVXAQEAZ-JNRFBPFXSA-N (5z,8s,9r,10e,12s)-9,12-dihydroxy-8-[(1s)-1-hydroxy-3-oxopropyl]heptadeca-5,10-dienoic acid Chemical compound CCCCC[C@H](O)\C=C\[C@@H](O)[C@H]([C@@H](O)CC=O)C\C=C/CCCC(O)=O FMNQRUKVXAQEAZ-JNRFBPFXSA-N 0.000 description 2
- RZYHXKLKJRGJGP-UHFFFAOYSA-N 2,2,2-trifluoro-n,n-bis(trimethylsilyl)acetamide Chemical compound C[Si](C)(C)N([Si](C)(C)C)C(=O)C(F)(F)F RZYHXKLKJRGJGP-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 238000000065 atmospheric pressure chemical ionisation Methods 0.000 description 2
- 230000001746 atrial effect Effects 0.000 description 2
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 238000013467 fragmentation Methods 0.000 description 2
- 238000006062 fragmentation reaction Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000000816 matrix-assisted laser desorption--ionisation Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 210000004115 mitral valve Anatomy 0.000 description 2
- 238000005457 optimization Methods 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 238000000672 surface-enhanced laser desorption--ionisation Methods 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000004704 ultra performance liquid chromatography Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 239000003643 water by type Substances 0.000 description 2
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- ATRRKUHOCOJYRX-UHFFFAOYSA-N Ammonium bicarbonate Chemical compound [NH4+].OC([O-])=O ATRRKUHOCOJYRX-UHFFFAOYSA-N 0.000 description 1
- 229910000013 Ammonium bicarbonate Inorganic materials 0.000 description 1
- 206010037423 Pulmonary oedema Diseases 0.000 description 1
- 206010042600 Supraventricular arrhythmias Diseases 0.000 description 1
- 235000012538 ammonium bicarbonate Nutrition 0.000 description 1
- 239000001099 ammonium carbonate Substances 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 150000005829 chemical entities Chemical class 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 238000013079 data visualisation Methods 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 238000009795 derivation Methods 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 239000000032 diagnostic agent Substances 0.000 description 1
- 229940039227 diagnostic agent Drugs 0.000 description 1
- 235000021196 dietary intervention Nutrition 0.000 description 1
- 125000005442 diisocyanate group Chemical group 0.000 description 1
- 230000010339 dilation Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 238000000534 ion trap mass spectrometry Methods 0.000 description 1
- 210000005246 left atrium Anatomy 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000002705 metabolomic analysis Methods 0.000 description 1
- 230000001431 metabolomic effect Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- QWDDFCKIEJCEMF-UHFFFAOYSA-N propane-1,2,3-triol 2-(trimethylazaniumyl)ethyl hydrogen phosphate Chemical compound OCC(O)CO.C[N+](C)(C)CCOP(O)([O-])=O QWDDFCKIEJCEMF-UHFFFAOYSA-N 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 208000005333 pulmonary edema Diseases 0.000 description 1
- 238000000275 quality assurance Methods 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000012916 structural analysis Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- RZWIIPASKMUIAC-VQTJNVASSA-N thromboxane Chemical compound CCCCCCCC[C@H]1OCCC[C@@H]1CCCCCCC RZWIIPASKMUIAC-VQTJNVASSA-N 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 238000003809 water extraction Methods 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/483—Physical analysis of biological material
- G01N33/487—Physical analysis of biological material of liquid biological material
- G01N33/49—Blood
- G01N33/491—Blood by separating the blood components
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
- G01N33/6806—Determination of free amino acids
- G01N33/6812—Assays for specific amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2570/00—Omics, e.g. proteomics, glycomics or lipidomics; Methods of analysis focusing on the entire complement of classes of biological molecules or subsets thereof, i.e. focusing on proteomes, glycomes or lipidomes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/32—Cardiovascular disorders
- G01N2800/326—Arrhythmias, e.g. ventricular fibrillation, tachycardia, atrioventricular block, torsade de pointes
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
- Y10T436/142222—Hetero-O [e.g., ascorbic acid, etc.]
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
- Y10T436/142222—Hetero-O [e.g., ascorbic acid, etc.]
- Y10T436/143333—Saccharide [e.g., DNA, etc.]
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/16—Phosphorus containing
- Y10T436/163333—Organic [e.g., chemical warfare agents, insecticides, etc.]
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/20—Oxygen containing
- Y10T436/200833—Carbonyl, ether, aldehyde or ketone containing
- Y10T436/201666—Carboxylic acid
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Physics & Mathematics (AREA)
- General Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Food Science & Technology (AREA)
- Pathology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Bioinformatics & Computational Biology (AREA)
- Endocrinology (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Ecology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
- Measuring And Recording Apparatus For Diagnosis (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Description
[0009]用語「動物」は、慢性弁膜疾患にかかりやすい又は罹患している任意の動物を意味する。
[0018]一態様において、本発明は、動物における慢性弁膜疾患を診断するための方法を提供する。本方法は、該動物から生体試料を得ることと、慢性弁膜疾患に関連する1つ又は複数の代謝産物の有無について該試料を分析することと、該試料中で同定された当該代謝産物それぞれの量を、慢性弁膜疾患に罹患していない1個体又は複数の比較対照動物由来の試料中に存在する同種の代謝産物の対応する量と比較することと、前記比較を用いて、該動物の試料中で認められた該代謝産物が、該対照動物の試料中に存在する該量より多ければ又は少なければ該動物には慢性弁膜疾患ありと診断することとを含む。当該試料中のある代謝産物の量又は濃度は、慢性弁膜疾患に罹患している動物においては増加することが既知であるが、当該試料中のある代謝産物の量又は濃度は、慢性弁膜疾患に罹患している動物においては減少することが既知である。診断は、量が増加することが既知である記載の代謝産物のみ、又は量が減少することが既知である記載の代謝産物のみ、又はそれらの組合せに基づいて行うことができる。
[0032]試験デザイン。血清試料は、イヌ科の動物の2つの代表群から採取した。対照群(11)は、心疾患の徴候を示さなかった動物であり、他方の群は、心疾患ありと過去に診断されたことがある被験動物(18)で構成された。試料を分析して代謝プロファイルを得、心疾患を示すバイオマーカーのデータを分析した。
[関連出願の相互参照]
Claims (20)
- 動物における慢性弁膜疾患を診断するための方法であって、
前記動物から生体試料を得るステップと、
慢性弁膜疾患に関連する1つ又は複数の代謝産物の有無について前記試料を分析するステップと、
前記試料中で同定された当該代謝産物それぞれの量を、慢性弁膜疾患に罹患していない1個体又は複数の比較対照動物由来の試料中に存在する同種の代謝産物の対応する量と比較するステップと、
前記比較を用いて、前記動物の試料中で認められた当該代謝産物それぞれの量が、前記対照動物の試料中に存在する前記量より多ければ前記動物には慢性弁膜疾患ありと診断するステップと
を含む方法。 - 前記試料が血清試料である、請求項1に記載の動物における慢性弁膜疾患を診断するための方法。
- 前記診断が、慢性弁膜疾患に関連する2つ以上の代謝産物の量を決定するステップに基づいて行われる、請求項1に記載の動物における慢性弁膜疾患を診断するための方法。
- 前記診断が、慢性弁膜疾患に関連する3つ以上の代謝産物の量を決定するステップに基づいて行われる、請求項1に記載の動物における慢性弁膜疾患を診断するための方法。
- 前記診断が、慢性弁膜疾患に関連する4つ以上の代謝産物の量を決定するステップに基づいて行われる、請求項1に記載の動物における慢性弁膜疾患を診断するための方法。
- 前記代謝産物が、グルタミン酸、C−グリコシルトリプトファン、β−ヒドロキシイソバレラート、酸化型グルタチオン、エリトロナート、N−アセチルノイラミナート、ラクタート、cis−アコニタート、スクシニルカルニチン、マラート、ペンタデカノアート(15:0)、マルガラート(17:0)、パルミチン酸メチル(15又は2)、12−HEPE、ヘキサノイルカルニチン、グリセロホスホリルコリン、1−ステアロイルグリセロホスホイノシトール、N6−カルバモイルトレオニルアデノシン、シチジン、パントテナート、N−グリコリルノイラミナート、X−11400、X−12729、X−13422、X−13543、X−14272、X−16277、12−HETE、及びトロンボキサンB2である、請求項1に記載の動物における慢性弁膜疾患を診断するための方法。
- 前記代謝産物が、酸化型グルタチオン、N−アセチルノイラミナート、ラクタート、スクシニルカルニチン、ヘキサノイルカルニチン、12−HETE、及びトロンボキサンB2である、請求項1に記載の動物における慢性弁膜疾患を診断するための方法。
- 前記動物がイヌ科の動物である、請求項1に記載の動物における慢性弁膜疾患を診断するための方法。
- 前記動物がイヌである、請求項1に記載の動物における慢性弁膜疾患を診断するための方法。
- 動物における慢性弁膜疾患を診断するための方法であって、
前記動物から生体試料を得るステップと、
慢性弁膜疾患に関連する1つ又は複数の代謝産物の有無について前記試料を分析するステップと、
前記試料中で同定された当該代謝産物それぞれの量を、慢性弁膜疾患に罹患していない1個体又は複数の比較対照動物由来の試料中に存在する同種の代謝産物の対応する量と比較するステップと、
前記比較を用いて、前記動物の試料中で認められた当該代謝産物それぞれの量が、前記対照動物の試料中に存在する前記量より少なければ前記動物には慢性弁膜疾患ありと診断するステップと
を含む方法。 - 前記試料が血清試料である、請求項10に記載の動物における慢性弁膜疾患を診断するための方法。
- 前記診断が、慢性弁膜疾患に関連する2つ以上の代謝産物の量を決定するステップに基づいて行われる、請求項10に記載の動物における慢性弁膜疾患を診断するための方法。
- 前記診断が、慢性弁膜疾患に関連する3つ以上の代謝産物の量を決定するステップに基づいて行われる、請求項10に記載の動物における慢性弁膜疾患を診断するための方法。
- 前記診断が、慢性弁膜疾患に関連する4つ以上の代謝産物の量を決定するステップに基づいて行われる、請求項10に記載の動物における慢性弁膜疾患を診断するための方法。
- 前記代謝産物が、サルコシン(N−メチルグリシン)、β−ヒドロキシピルバート、セリン、トレオニン、バリン、メチオニン、ジメチルアルギニン(SDMA+ADMA)、γ−グルタミルメチオニン、グルコース、2−ヒドロキシオクタノアート、デオキシカルニチン、1−パルミトレオイルグリセロホスホコリン、1−オレオイルグリセロホスホコリン、2−オレオイルグリセロホスホコリン、1−リノレオイルグリセロホスホコリン、2−リノレオイルグリセロホスホコリン、1−エイコサジエノイルグリセロホスホコリン、1−アラキドノイルグリセロホスホコリン、1−ドコサペンタエノイルグリセロホスホコリン、4−ヒドロキシマンデラート、X−03088、X−04357、X−11793、X−11818、X−12771、X−12786、及びX−13494である、請求項10に記載の動物における慢性弁膜疾患を診断するための方法。
- 前記代謝産物が、ジメチルアルギニン(SDMA+ADMA)、グルコース、及びデオキシカルニチンである、請求項10に記載の動物における慢性弁膜疾患を診断するための方法。
- 前記動物がイヌ科の動物である、請求項10に記載の動物における慢性弁膜疾患を診断するための方法。
- 前記動物がイヌである、請求項10に記載の動物における慢性弁膜疾患を診断するための方法。
- イヌ科の動物において慢性弁膜疾患を診断するための方法であって、
前記イヌ科の動物から生体試料を得るステップと、
慢性弁膜疾患に関連する2つ以上の代謝産物の有無について前記試料を分析するステップと、
前記試料中で同定された当該代謝産物それぞれの量を、慢性弁膜疾患に罹患していない1個体又は複数のイヌ科の比較対照動物由来の試料中に存在する同種の代謝産物の対応する量と比較するステップと、
前記比較を用いて、前記イヌ科の動物の試料中で認められた当該代謝産物それぞれの量が、前記イヌ科の対照動物の試料中に存在する前記量より少なければ前記イヌ科の動物には慢性弁膜疾患ありと診断するステップであり、前記代謝産物が、サルコシン(N−メチルグリシン)、β−ヒドロキシピルバート、セリン、トレオニン、バリン、メチオニン、ジメチルアルギニン(SDMA+ADMA)、γ−グルタミルメチオニン、グルコース、2−ヒドロキシオクタノアート、デオキシカルニチン、1−パルミトレオイルグリセロホスホコリン、1−オレオイルグリセロホスホコリン、2−オレオイルグリセロホスホコリン、1−リノレオイルグリセロホスホコリン、2−リノレオイルグリセロホスホコリン、1−エイコサジエノイルグリセロホスホコリン、1−アラキドノイルグリセロホスホコリン、1−ドコサペンタエノイルグリセロホスホコリン、4−ヒドロキシマンデラート、X−03088、X−04357、X−11793、X−11818、X−12771、X−12786、及びX−13494であるステップ、又は前記イヌ科の対照動物の試料中に存在する前記量より多ければ前記イヌ科の動物には慢性弁膜疾患ありと診断するステップであり、前記代謝産物が、グルタミン酸、C−グリコシルトリプトファン、β−ヒドロキシイソバレラート、酸化型グルタチオン、エリトロナート、N−アセチルノイラミナート、ラクタート、cis−アコニタート、スクシニルカルニチン、マラート、ペンタデカノアート(15:0)、マルガラート(17:0)、パルミチン酸メチル(15又は2)、12−HEPE、ヘキサノイルカルニチン、グリセロホスホリルコリン、1−ステアロイルグリセロホスホイノシトール、N6−カルバモイルトレオニルアデノシン、シチジン、パントテナート、N−グリコリルノイラミナート、X−11400、X−12729、X−13422、X−13543、X−14272、X−16277、12−HETE、及びトロンボキサンB2であるステップ、或いはその組合せであるステップと
を含む方法。 - 前記代謝産物が、ジメチルアルギニン(SDMA+ADMA)、グルコース、デオキシカルニチン、酸化型グルタチオン、N−アセチルノイラミナート、ラクタート、スクシニルカルニチン、ヘキサノイルカルニチン、12−HETE、トロンボキサンB2、又はそれらの組合せである、請求項19に記載のイヌ科の動物において慢性弁膜疾患を診断するための方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261655704P | 2012-06-05 | 2012-06-05 | |
US61/655,704 | 2012-06-05 | ||
PCT/US2013/044008 WO2013184628A1 (en) | 2012-06-05 | 2013-06-04 | Methods for diagnosing chronic valvular disease |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2015524066A true JP2015524066A (ja) | 2015-08-20 |
JP6174689B2 JP6174689B2 (ja) | 2017-08-02 |
Family
ID=48626663
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2015516104A Active JP6174689B2 (ja) | 2012-06-05 | 2013-06-04 | 慢性弁膜疾患を診断するための方法 |
Country Status (12)
Country | Link |
---|---|
US (1) | US20150153353A1 (ja) |
EP (1) | EP2856170B1 (ja) |
JP (1) | JP6174689B2 (ja) |
CN (1) | CN104364658B (ja) |
AU (1) | AU2013271879B2 (ja) |
BR (1) | BR112014030243B1 (ja) |
CA (1) | CA2875331C (ja) |
ES (1) | ES2687979T3 (ja) |
IN (1) | IN2014DN10127A (ja) |
MX (1) | MX358561B (ja) |
RU (1) | RU2667634C2 (ja) |
WO (1) | WO2013184628A1 (ja) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3387446A2 (en) * | 2015-12-07 | 2018-10-17 | Zora Biosciences OY | Use of ceramides and lpls in diagnosing cvd |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2010537157A (ja) * | 2007-07-17 | 2010-12-02 | メタボロン インコーポレイテッド | 糖尿病前症、心血管疾患及びその他のメタボリックシンドローム関連障害のバイオマーカー並びにその使用方法 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060257943A1 (en) * | 2005-01-25 | 2006-11-16 | Cis Biotech, Inc. | Ischemic biomarkers and their use to predict adverse neurological events from surgery |
CN101951924B (zh) * | 2007-11-09 | 2015-06-24 | 得克萨斯系统大学董事会 | Mir-15家族的微小rna调控心肌细胞存活和心脏修复 |
CN102119332A (zh) * | 2008-04-29 | 2011-07-06 | 免疫刺激公司 | 免疫调节组合物及其使用方法 |
CA2723130A1 (en) * | 2008-05-07 | 2009-11-12 | University Of Strathclyde | A system and method for cell characterisation |
TW201031421A (en) * | 2009-01-29 | 2010-09-01 | Abbott Lab | IL-1 binding proteins |
SG10201505724SA (en) * | 2010-07-23 | 2015-09-29 | Harvard College | Methods of detecting diseases or conditions using phagocytic cells |
-
2013
- 2013-06-04 EP EP13729199.3A patent/EP2856170B1/en active Active
- 2013-06-04 WO PCT/US2013/044008 patent/WO2013184628A1/en active Application Filing
- 2013-06-04 IN IN10127DEN2014 patent/IN2014DN10127A/en unknown
- 2013-06-04 US US14/405,325 patent/US20150153353A1/en not_active Abandoned
- 2013-06-04 CA CA2875331A patent/CA2875331C/en active Active
- 2013-06-04 CN CN201380029514.3A patent/CN104364658B/zh active Active
- 2013-06-04 RU RU2014153109A patent/RU2667634C2/ru active
- 2013-06-04 MX MX2014014791A patent/MX358561B/es active IP Right Grant
- 2013-06-04 ES ES13729199.3T patent/ES2687979T3/es active Active
- 2013-06-04 AU AU2013271879A patent/AU2013271879B2/en active Active
- 2013-06-04 JP JP2015516104A patent/JP6174689B2/ja active Active
- 2013-06-04 BR BR112014030243-0A patent/BR112014030243B1/pt active IP Right Grant
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2010537157A (ja) * | 2007-07-17 | 2010-12-02 | メタボロン インコーポレイテッド | 糖尿病前症、心血管疾患及びその他のメタボリックシンドローム関連障害のバイオマーカー並びにその使用方法 |
Non-Patent Citations (1)
Title |
---|
ARMELLE M. DE LAFORCADE ET AL.: "Serum Nitrate and Nitrite in Dogs with Spontaneous Cardiac Disease", J. VET. INTERN. MED., vol. 17, no. 3, JPN6017004350, 1 May 2003 (2003-05-01), pages 315 - 318, XP055069815, ISSN: 0003576125 * |
Also Published As
Publication number | Publication date |
---|---|
US20150153353A1 (en) | 2015-06-04 |
CN104364658B (zh) | 2017-06-30 |
RU2667634C2 (ru) | 2018-09-21 |
BR112014030243B1 (pt) | 2022-07-05 |
MX2014014791A (es) | 2015-02-24 |
CA2875331A1 (en) | 2013-12-12 |
IN2014DN10127A (ja) | 2015-08-21 |
BR112014030243A2 (pt) | 2017-06-27 |
ES2687979T3 (es) | 2018-10-30 |
AU2013271879A1 (en) | 2014-12-18 |
AU2013271879B2 (en) | 2019-03-28 |
CN104364658A (zh) | 2015-02-18 |
EP2856170A1 (en) | 2015-04-08 |
EP2856170B1 (en) | 2018-07-25 |
CA2875331C (en) | 2022-11-29 |
RU2014153109A (ru) | 2016-08-10 |
WO2013184628A1 (en) | 2013-12-12 |
JP6174689B2 (ja) | 2017-08-02 |
MX358561B (es) | 2018-08-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Muthubharathi et al. | Metabolomics: small molecules that matter more | |
Bruderer et al. | Optimization of experimental parameters in data-independent mass spectrometry significantly increases depth and reproducibility of results | |
Courant et al. | Basics of mass spectrometry based metabolomics | |
Theodoridis et al. | Mass spectrometry‐based holistic analytical approaches for metabolite profiling in systems biology studies | |
Levin et al. | Quantification of proteins using data‐independent analysis (MSE) in simple andcomplex samples: a systematic evaluation | |
Stoop et al. | Quantitative proteomics and metabolomics analysis of normal human cerebrospinal fluid samples | |
Xue et al. | Enhanced in-source fragmentation annotation enables novel data independent acquisition and autonomous METLIN molecular identification | |
Gertsman et al. | Validation of a dual LC–HRMS platform for clinical metabolic diagnosis in serum, bridging quantitative analysis and untargeted metabolomics | |
Kuehnbaum et al. | Multiplexed separations for biomarker discovery in metabolomics: Elucidating adaptive responses to exercise training | |
Burnum-Johnson et al. | Simultaneous proteomic discovery and targeted monitoring using liquid chromatography, ion mobility spectrometry, and mass spectrometry | |
Evans et al. | Categorizing ion-features in liquid chromatography | |
Gaudin et al. | Ultra performance liquid chromatography–mass spectrometry studies of formalin‐induced alterations of human brain lipidome | |
van der Hooft et al. | Enhanced acylcarnitine annotation in high-resolution mass spectrometry data: fragmentation analysis for the classification and annotation of acylcarnitines | |
Heaven et al. | Systematic evaluation of data‐independent acquisition for sensitive and reproducible proteomics—a prototype design for a single injection assay | |
Qiu et al. | Gas chromatography in metabolomics study | |
Musharraf et al. | Metabolite profiling of human plasma by different extraction methods through gas chromatography–mass spectrometry—An objective comparison | |
Alves et al. | Mass spectrometry-based metabolomics for an in-depth questioning of human health | |
Wishart et al. | Metabolomics | |
JP6174689B2 (ja) | 慢性弁膜疾患を診断するための方法 | |
EP3482213A1 (en) | Diagnostic methods based on lipid profiles | |
CN114280202A (zh) | 一种用于诊断镉中毒的生物标志物及其应用 | |
Tu et al. | A peptide-retrieval strategy enables significant improvement of quantitative performance without compromising confidence of identification | |
Chen et al. | Evaluation of the Feasibility of Metabolome Analyses for the Identification of Body Fluids | |
Gil et al. | Metabolomics of Body Fluids | |
Tada | Data Analysis Platform for All-Ion Fragmentation Mass Spectrometry |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20160526 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20170208 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20170214 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170510 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20170613 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20170706 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6174689 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313111 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |